晚期非小细胞肺癌患者吉非替尼治疗前后血清癌胚抗原水平变化及意义

Significance of carcinoembryonic antigen level changes before and after treated with gefitinib in patients with advanced non-small cell lung cancer

  • 摘要: 目的:探讨晚期非小细胞肺癌患者经吉非替尼治疗前后血清癌胚抗原(CEA)水平的变化及意义。方法40例Ⅲ~Ⅳ期晚期非小细胞肺癌患者为研究对象,入院后给予吉非替尼治疗,同时给予患者常规局部放疗,直到患者肿瘤进展或难以耐受时停药。所有患者治疗前、后均行血清 CEA 检测,根据治疗前的 CEA 水平将40例患者分为高 CEA 组和低 CEA 组,随访至2013年12月,观察2组患者不良反应发生情况及无进展生存时间(PFS)。治疗结束后,根据评价结果分为控制组和非控制组,观察2组血清 CEA 水平的变化。结果治疗前,控制组和非控制组血清 CEA 水平无显著差异(P >0.05);治疗后,2组血清 CEA 水平较治疗前明显降低(P <0.01)。控制组治疗后血清 CEA 水平明显低于非控制组(P <0.01)。高 CEA 组不良反应发生率均高于低 CEA 组,但2组不良反应发生率无统计学差异(P >0.05)。CEA 高水平患者9个月、12个月的生存率明显高于 CEA 低水平的患者(P <0.05)。结论血清 CEA 水平可以作为评估吉非替尼治疗晚期非小细胞肺癌的预后生化指标。

     

    Abstract: Objective To discuss significance of carcinoembryonic antigen level changes be-fore and after the treatment of gefinitib in patients with non-small cell lung cancer(NSCLC). Methods 40 patients with advanced NSCLC in Ⅲ~Ⅳ period were enrolled and given routine local chemotherapy and gEfitinib,and the therapy was which until the patients were intolerant to it.All the patients were given carcinoembryonic antigen (CEA)test before and after treatment and were divided into high CEA group and low CEA group according to CEA level before treatment.Follow-up lasted until December 2013,adverse reactions and PFS in 2 groups were observed.Results Before treatment,the difference was not significant in CEA levels in control group and uncontrolled group (P >0.05).After treatment,CEA levels in 2 groups were obviously lower than the treat-ment before (P <0.01)and CEA level in control group was obviously lower than that in the uncon-trolled group(P <0.01).Occurrence rate of adverse reactions in high CEA group was higher than low CEA group but the difference were not significant (P >0.05).Survival rates of 9 and 12 months in high CEA group were markedly higher than that in thee low CEA group (P <0.05). Conclusion CEA level can be considered as a biochemical index of assessing prognosis of gefitinib in treatment of advanced NSCLC.

     

/

返回文章
返回